Health & Safety Industry Today
Liquid Biopsy Market Rapid Growth: USD 3.73 Billion in 2025 to USD 14.07 Billion by 2032 at 20.9% CAGR
Market Overview
The Liquid Biopsy Market was valued at USD 3.73 Billion in 2025 and is expected to grow at a CAGR of 20.9% from 2026 to 2032, reaching nearly USD 14.07 Billion by 2032. Liquid biopsy is a quick, non-invasive and repeatable sampling approach that can reflect tumor gene-expression changes and support customized treatment, early detection, therapy-response assessment and identification of recurrent or refractory cancer.
Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/3261/
Technological advances in practicality and turnaround time are increasing interest in liquid biopsy as an alternative to conventional tissue biopsy. The market covers assay kits and instruments, NGS and PCR/microarray technologies, cancer and non-cancer applications, and use across reference laboratories and hospitals. Precision oncology and the need for repeatable molecular monitoring are increasing its clinical relevance.
Key Growth Drivers Fueling the Liquid Biopsy Market
Rising cancer incidence and prevalence. MMR identifies the growing cancer burden as a central driver. Liquid biopsy can support early prognosis, therapy monitoring, assessment of tumor heterogeneity and acquired drug resistance while reducing dependence on surgical sampling.
Demand for non-invasive and repeatable testing. Blood- and fluid-based testing can be repeated more easily than tissue biopsy, supporting longitudinal monitoring. This makes the approach relevant for treatment assessment, recurrence detection and precision cancer diagnostics.
Expansion of companion diagnostics. MMR highlights companion diagnostics as a major opportunity because biomarker-guided tests can help doctors select therapies according to patient response and molecular characteristics.
Advances in next-generation sequencing. Multi-gene parallel analysis using NGS accounted for over 73% of global market revenue in 2023 and is expected to remain the dominant technology. NGS enables broad mutation detection and sensitive ctDNA analysis.
Innovation in biomarkers and exosomes. Circulating nucleic acids lead the biomarker category with a 36.67% share, while exosomes/microvesicles are expected to record the fastest CAGR through the forecast period.
Market Segmentation — By Product, Technology, Application & End-Use
- Product: Assay Kits; Instruments.
- Technology: Multi-gene-parallel Analysis (NGS); Single Gene Analysis (PCR Microarrays). NGS accounted for over 73% of global revenue in 2023.
- Application: Cancer; Non-Cancer.
- End User: Reference Lab; Hospitals.
- Biomarker highlighted by MMR: Circulating Nucleic Acids — 36.67% share; Exosomes/Microvesicles are expected to show the fastest CAGR.
NGS is the dominant technology because it can screen multiple mutations, identify resistance mechanisms and support sensitive ctDNA analysis. Circulating nucleic acids lead the biomarker category because ctDNA supports molecular diagnosis, surveillance and targeted-therapy decisions. MMR does not publish percentage shares for product, application or end-user categories in the accessible summary.
Regional Analysis — Where Is the Liquid Biopsy Market Growing Fastest?
United States
The United States dominates the North American regional market, supported by higher investment and numerous biotechnology companies producing tests. MMR also notes support from organizations including the American Society of Clinical Oncology.
United Kingdom
The United Kingdom is included in MMR’s Europe country analysis. The accessible summary does not publish a UK-specific market size, share or CAGR.
Germany
Germany is part of MMR’s European country coverage. No Germany-specific value, percentage share or growth rate is disclosed in the public summary.
Japan
Japan is included in MMR’s Asia Pacific analysis, and Sysmex Corporation and Takara Bio are listed among Japan-based industry participants. No Japan-specific market percentage is published.
South Korea
South Korea is covered within MMR’s Asia Pacific analysis. The accessible description does not provide a separate South Korean size, share or CAGR.
China
China is included in Asia Pacific coverage, while Burning Rock Biotech, BGI Genomics and MGI Tech are listed as China-based participants. The summary does not disclose a China-specific share.
India
India is included in the Asia Pacific country-level scope. MMR’s public description does not state an India-specific value or percentage share.
North America is the dominant region in the Liquid Biopsy Market with a 51% share, supported by investment, biotechnology-company presence and adoption of approved tests. The accessible summary does not identify a separate fastest-growing region, so no unsupported regional CAGR is assigned.
Competitive Landscape Leading Companies in the Liquid Biopsy Market
- Guardant Health Identified by MMR as a commercial testing and precision cancer diagnostics leader focused on cancer detection, monitoring, recurrence assessment and precision oncology.
- Exact Sciences Listed among leading commercial testing companies and multi-cancer early detection participants.
- Natera Positioned among commercial liquid biopsy leaders, with recent oncology portfolio expansion through acquisition.
- Biocept Included in MMR’s leading group of commercial precision cancer diagnostic companies.
- Burning Rock Biotech A China-based leader listed in commercial testing and multi-cancer early detection.
These companies compete across clinically validated blood-based testing, genomic profiling, recurrence monitoring, early detection and precision oncology workflows, making innovation and clinical adoption central to the Liquid Biopsy Market competitive landscape.
Download PDF Brochure: https://www.maximizemarketresearch.com/request-sample/3261/
Recent Developments & Strategic Moves
- On February 19, 2026, GRAIL released topline NHS-Galleri trial results involving more than 142,000 participants, supporting its multi-cancer early detection test.
- On January 15, 2026, Illumina unveiled its Billion Cell Atlas and expansion into AI-driven liquid biopsy workflows for minimal residual disease testing and drug discovery.
- On December 9, 2025, Guardant Health launched FPG 360 at Policlinico Gemelli in Italy using Guardant360 CDx technology for local comprehensive genomic profiling.
- On December 5, 2025, Natera completed its acquisition of Foresight Diagnostics for approximately USD 275 million to strengthen its oncology portfolio.
- On September 10, 2025, Exact Sciences commercially launched Cancerguard, a multi-cancer early detection blood test targeting more than 50 cancer types.
AI & Digital Transformation Impact on Liquid Biopsy Market
AI is changing the Liquid Biopsy Market by becoming more closely integrated with genomic analysis, minimal residual disease workflows and large-scale biological-data interpretation. MMR highlights Illumina’s January 2026 expansion into AI-driven liquid biopsy workflows alongside the Billion Cell Atlas, showing how digital analysis is entering the core molecular-diagnostics technology stack.
Automation and computational analysis can support interpretation of complex sequencing signals, workflow standardization and pattern recognition. Combined with NGS and biomarker analysis, AI-supported workflows can help laboratories translate blood-based genomic information into more actionable diagnostic and treatment insights.
Future Outlook Investment Opportunities & Emerging Trends
The future of the Liquid Biopsy Market is tied to broader adoption of NGS, circulating nucleic acid analysis, exosome-based diagnostics, companion diagnostics, multi-cancer early detection and minimal residual disease testing. Opportunities are emerging around validated assay kits, sequencing platforms, laboratory automation and AI-supported genomic interpretation. With North America holding the documented regional lead and major companies investing in acquisitions and commercialization, strategic attention is likely to remain on improving sensitivity, simplifying testing and extending blood-based diagnostics toward earlier cancer detection.
Expert Commentary
"According to Komal Patil, Research Manager at Maximize Market Research, 'The Liquid Biopsy Market is projected to expand from USD 3.73 Billion in 2025 to nearly USD 14.07 Billion by 2032 at a CAGR of 20.9% from 2026 to 2032. NGS leadership, circulating nucleic acid testing, multi-cancer early detection and AI-enabled genomic workflows are creating opportunities for companies that combine clinical validation with scalable precision-diagnostics platforms.'"
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.
Contact Us
2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
sales@maximizemarketresearch.com
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
